Ryan Fischer
Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 15 | 2023 | 39 | 5.240 |
Why?
| | Liver Diseases | 6 | 2023 | 17 | 2.230 |
Why?
| | Muscular Dystrophy, Duchenne | 9 | 2024 | 16 | 1.320 |
Why?
| | Humans | 52 | 2026 | 8529 | 1.310 |
Why?
| | Alagille Syndrome | 5 | 2025 | 5 | 1.110 |
Why?
| | Male | 32 | 2025 | 4255 | 1.020 |
Why?
| | Immunosuppressive Agents | 6 | 2019 | 38 | 1.020 |
Why?
| | Sirolimus | 6 | 2019 | 9 | 0.970 |
Why?
| | Child | 29 | 2025 | 4199 | 0.960 |
Why?
| | Postoperative Complications | 4 | 2020 | 194 | 0.900 |
Why?
| | Female | 27 | 2025 | 4443 | 0.850 |
Why?
| | Fontan Procedure | 2 | 2021 | 26 | 0.820 |
Why?
| | Thrombosis | 1 | 2023 | 20 | 0.800 |
Why?
| | Dendritic Cells | 4 | 2011 | 8 | 0.800 |
Why?
| | Child, Preschool | 18 | 2025 | 2010 | 0.720 |
Why?
| | Patient Compliance | 2 | 2020 | 64 | 0.680 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 11 | 0.670 |
Why?
| | Cryptosporidiosis | 1 | 2020 | 2 | 0.670 |
Why?
| | Immunocompromised Host | 1 | 2020 | 13 | 0.660 |
Why?
| | Infant | 17 | 2025 | 1841 | 0.650 |
Why?
| | Retrospective Studies | 15 | 2023 | 1603 | 0.640 |
Why?
| | Adolescent | 19 | 2025 | 2766 | 0.630 |
Why?
| | Cholangitis, Sclerosing | 3 | 2026 | 3 | 0.620 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2019 | 3 | 0.610 |
Why?
| | Neoplasms | 1 | 2021 | 151 | 0.610 |
Why?
| | Hydrops Fetalis | 1 | 2019 | 6 | 0.600 |
Why?
| | Electronic Health Records | 1 | 2019 | 85 | 0.590 |
Why?
| | Graft Rejection | 3 | 2020 | 34 | 0.550 |
Why?
| | Foot Dermatoses | 1 | 2017 | 1 | 0.540 |
Why?
| | Pagetoid Reticulosis | 1 | 2017 | 1 | 0.540 |
Why?
| | Skin Neoplasms | 1 | 2017 | 10 | 0.530 |
Why?
| | Immune Tolerance | 3 | 2021 | 11 | 0.520 |
Why?
| | Intestines | 2 | 2013 | 37 | 0.510 |
Why?
| | Adult | 12 | 2025 | 1446 | 0.500 |
Why?
| | Treatment Outcome | 12 | 2026 | 717 | 0.490 |
Why?
| | Bile Acids and Salts | 3 | 2025 | 3 | 0.480 |
Why?
| | Vancomycin | 3 | 2026 | 19 | 0.470 |
Why?
| | Animals | 6 | 2021 | 817 | 0.460 |
Why?
| | Intestinal Atresia | 1 | 2013 | 9 | 0.420 |
Why?
| | Caregivers | 4 | 2025 | 58 | 0.420 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2013 | 18 | 0.420 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2022 | 17 | 0.400 |
Why?
| | Hypertension, Portal | 2 | 2022 | 5 | 0.380 |
Why?
| | Isoantigens | 2 | 2011 | 2 | 0.370 |
Why?
| | Myeloid Cells | 1 | 2011 | 3 | 0.350 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2022 | 22 | 0.350 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2011 | 12 | 0.350 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 18 | 0.350 |
Why?
| | Hepatolenticular Degeneration | 1 | 2011 | 1 | 0.350 |
Why?
| | Anti-Bacterial Agents | 3 | 2026 | 313 | 0.350 |
Why?
| | Cholestasis, Intrahepatic | 2 | 2021 | 3 | 0.330 |
Why?
| | Genetic Therapy | 2 | 2021 | 9 | 0.330 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 120 | 0.330 |
Why?
| | Fatty Liver | 2 | 2013 | 6 | 0.330 |
Why?
| | Short Bowel Syndrome | 3 | 2015 | 6 | 0.320 |
Why?
| | Young Adult | 9 | 2025 | 838 | 0.320 |
Why?
| | Patient Participation | 2 | 2020 | 20 | 0.310 |
Why?
| | Patient Preference | 3 | 2019 | 7 | 0.300 |
Why?
| | Prospective Studies | 4 | 2023 | 595 | 0.290 |
Why?
| | Cholestasis | 2 | 2025 | 5 | 0.260 |
Why?
| | Liver Failure | 2 | 2019 | 2 | 0.240 |
Why?
| | United States | 5 | 2025 | 829 | 0.240 |
Why?
| | Growth Charts | 1 | 2025 | 6 | 0.240 |
Why?
| | Liver Cirrhosis | 3 | 2023 | 7 | 0.240 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2026 | 40 | 0.240 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2020 | 8 | 0.230 |
Why?
| | Angelman Syndrome | 1 | 2025 | 2 | 0.230 |
Why?
| | Forkhead Transcription Factors | 2 | 2020 | 11 | 0.230 |
Why?
| | Transition to Adult Care | 2 | 2022 | 22 | 0.220 |
Why?
| | Pruritus | 1 | 2024 | 5 | 0.220 |
Why?
| | Quality of Life | 3 | 2025 | 191 | 0.210 |
Why?
| | Comprehension | 1 | 2023 | 6 | 0.210 |
Why?
| | Cardiomyopathies | 1 | 2024 | 12 | 0.210 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2023 | 3 | 0.210 |
Why?
| | Aspirin | 1 | 2023 | 7 | 0.210 |
Why?
| | Hepatic Artery | 1 | 2023 | 3 | 0.210 |
Why?
| | Vascular Diseases | 1 | 2023 | 5 | 0.200 |
Why?
| | Anticoagulants | 1 | 2023 | 22 | 0.200 |
Why?
| | Insurance | 1 | 2023 | 4 | 0.200 |
Why?
| | Intestine, Small | 2 | 2013 | 18 | 0.200 |
Why?
| | Digestive System Diseases | 1 | 2022 | 1 | 0.190 |
Why?
| | Gastroenterology | 1 | 2022 | 8 | 0.190 |
Why?
| | Bilirubin | 4 | 2025 | 26 | 0.180 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 17 | 0.180 |
Why?
| | Patient Advocacy | 3 | 2019 | 10 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 14 | 0.180 |
Why?
| | Heart Transplantation | 2 | 2020 | 20 | 0.180 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2022 | 18 | 0.180 |
Why?
| | Prognosis | 3 | 2025 | 250 | 0.180 |
Why?
| | Risk Assessment | 5 | 2021 | 177 | 0.180 |
Why?
| | Adenosine Triphosphatases | 1 | 2021 | 3 | 0.180 |
Why?
| | T-Lymphocytes | 2 | 2013 | 35 | 0.180 |
Why?
| | Cohort Studies | 2 | 2020 | 341 | 0.180 |
Why?
| | Tacrolimus | 2 | 2019 | 11 | 0.170 |
Why?
| | Attitude | 1 | 2021 | 15 | 0.170 |
Why?
| | Aged, 80 and over | 2 | 2021 | 170 | 0.170 |
Why?
| | Biliary Tract Diseases | 1 | 2020 | 4 | 0.170 |
Why?
| | Diarrhea | 1 | 2020 | 23 | 0.170 |
Why?
| | Weight Reduction Programs | 1 | 2020 | 27 | 0.170 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 95 | 0.160 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2020 | 2 | 0.160 |
Why?
| | Liver Function Tests | 1 | 2019 | 4 | 0.160 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 14 | 0.160 |
Why?
| | Antipsychotic Agents | 1 | 2019 | 14 | 0.160 |
Why?
| | Anticonvulsants | 1 | 2019 | 35 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2011 | 16 | 0.150 |
Why?
| | Graft Survival | 1 | 2019 | 34 | 0.150 |
Why?
| | Incidence | 1 | 2019 | 139 | 0.150 |
Why?
| | Technology Assessment, Biomedical | 1 | 2019 | 2 | 0.150 |
Why?
| | Ion Channels | 1 | 2019 | 3 | 0.150 |
Why?
| | Uncertainty | 1 | 2019 | 12 | 0.150 |
Why?
| | Ascites | 1 | 2019 | 4 | 0.150 |
Why?
| | Research | 1 | 2019 | 17 | 0.150 |
Why?
| | Hepatoblastoma | 1 | 2019 | 6 | 0.150 |
Why?
| | Choice Behavior | 1 | 2019 | 15 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2019 | 14 | 0.150 |
Why?
| | Decision Making | 1 | 2019 | 38 | 0.150 |
Why?
| | Drainage | 1 | 2019 | 38 | 0.150 |
Why?
| | Transplantation Tolerance | 2 | 2010 | 2 | 0.150 |
Why?
| | Middle Aged | 4 | 2025 | 738 | 0.150 |
Why?
| | Thrombelastography | 1 | 2018 | 1 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 133 | 0.140 |
Why?
| | Blood Transfusion | 1 | 2018 | 11 | 0.140 |
Why?
| | Necrobiotic Xanthogranuloma | 1 | 2018 | 1 | 0.140 |
Why?
| | Dissection | 1 | 2018 | 4 | 0.140 |
Why?
| | Resuscitation | 1 | 2018 | 12 | 0.140 |
Why?
| | Cicatrix | 1 | 2018 | 6 | 0.140 |
Why?
| | Infant, Premature | 1 | 2019 | 123 | 0.140 |
Why?
| | Skin | 1 | 2018 | 21 | 0.140 |
Why?
| | Liver | 2 | 2022 | 126 | 0.140 |
Why?
| | Pregnancy | 1 | 2019 | 257 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2018 | 43 | 0.140 |
Why?
| | Infant, Newborn | 4 | 2025 | 1078 | 0.140 |
Why?
| | Pediatric Obesity | 1 | 2020 | 179 | 0.130 |
Why?
| | Melanoma | 1 | 2017 | 7 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 7 | 0.130 |
Why?
| | Intestinal Diseases | 2 | 2013 | 4 | 0.130 |
Why?
| | Patient-Centered Care | 3 | 2021 | 22 | 0.130 |
Why?
| | Health Resources | 1 | 2015 | 24 | 0.120 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 9 | 0.120 |
Why?
| | Mice | 3 | 2011 | 427 | 0.110 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 198 | 0.110 |
Why?
| | Membrane Glycoproteins | 2 | 2024 | 13 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 31 | 0.110 |
Why?
| | Stem Cell Transplantation | 1 | 2013 | 16 | 0.110 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 27 | 0.110 |
Why?
| | Carrier Proteins | 2 | 2024 | 42 | 0.100 |
Why?
| | Graft vs Host Disease | 1 | 2013 | 16 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2013 | 204 | 0.100 |
Why?
| | Parenteral Nutrition, Total | 1 | 2013 | 5 | 0.100 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2013 | 1 | 0.100 |
Why?
| | Calcineurin | 1 | 2013 | 1 | 0.100 |
Why?
| | Pancreas Transplantation | 1 | 2013 | 2 | 0.100 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 4 | 0.100 |
Why?
| | Fish Oils | 1 | 2013 | 2 | 0.100 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2013 | 2 | 0.100 |
Why?
| | Apoptosis | 1 | 2012 | 57 | 0.090 |
Why?
| | Portal Vein | 2 | 2023 | 6 | 0.090 |
Why?
| | Lymphocyte Activation | 2 | 2009 | 9 | 0.090 |
Why?
| | Aged | 2 | 2025 | 440 | 0.090 |
Why?
| | Transplantation, Isogeneic | 1 | 2011 | 1 | 0.090 |
Why?
| | Cell Survival | 1 | 2011 | 21 | 0.090 |
Why?
| | Mice, Knockout | 1 | 2011 | 72 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 370 | 0.090 |
Why?
| | Body Height | 2 | 2025 | 50 | 0.080 |
Why?
| | Body Mass Index | 2 | 2022 | 195 | 0.080 |
Why?
| | Biopsy | 3 | 2018 | 63 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2021 | 310 | 0.080 |
Why?
| | Chemotaxis | 1 | 2009 | 2 | 0.080 |
Why?
| | Antigen Presentation | 1 | 2009 | 3 | 0.080 |
Why?
| | Immunotherapy, Adoptive | 1 | 2009 | 7 | 0.080 |
Why?
| | Metformin | 1 | 2009 | 10 | 0.070 |
Why?
| | B-Lymphocytes | 1 | 2009 | 27 | 0.070 |
Why?
| | Cytokines | 1 | 2009 | 58 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 71 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2009 | 55 | 0.070 |
Why?
| | Recurrence | 2 | 2019 | 112 | 0.070 |
Why?
| | Signal Transduction | 1 | 2009 | 136 | 0.070 |
Why?
| | Data Collection | 2 | 2021 | 29 | 0.070 |
Why?
| | Obesity | 1 | 2009 | 154 | 0.070 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 1 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 7 | 0.060 |
Why?
| | Steroids | 2 | 2019 | 21 | 0.060 |
Why?
| | Pediatrics | 2 | 2019 | 227 | 0.060 |
Why?
| | Disease Progression | 2 | 2019 | 130 | 0.060 |
Why?
| | Administration, Oral | 1 | 2026 | 71 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 39 | 0.060 |
Why?
| | Body Weight | 1 | 2025 | 77 | 0.060 |
Why?
| | Cost of Illness | 1 | 2025 | 24 | 0.060 |
Why?
| | United States Food and Drug Administration | 2 | 2015 | 7 | 0.060 |
Why?
| | Health Care Costs | 1 | 2025 | 33 | 0.060 |
Why?
| | Thiazepines | 1 | 2024 | 1 | 0.050 |
Why?
| | Methylamines | 1 | 2024 | 4 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2024 | 57 | 0.050 |
Why?
| | Exons | 1 | 2024 | 51 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 3 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 22 | 0.050 |
Why?
| | Registries | 1 | 2023 | 91 | 0.050 |
Why?
| | Parenteral Nutrition | 1 | 2023 | 9 | 0.050 |
Why?
| | Biomarkers | 1 | 2024 | 180 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2022 | 17 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 16 | 0.050 |
Why?
| | Prevalence | 1 | 2023 | 193 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2022 | 5 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 12 | 0.050 |
Why?
| | Patient Transfer | 1 | 2022 | 10 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2022 | 51 | 0.050 |
Why?
| | Societies, Medical | 1 | 2022 | 66 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2022 | 9 | 0.050 |
Why?
| | Vaccination | 1 | 2022 | 89 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 13 | 0.050 |
Why?
| | Urban Population | 1 | 2022 | 36 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2021 | 1 | 0.040 |
Why?
| | Codon, Nonsense | 1 | 2021 | 8 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 45 | 0.040 |
Why?
| | Patients | 1 | 2021 | 5 | 0.040 |
Why?
| | Risk-Taking | 1 | 2021 | 11 | 0.040 |
Why?
| | Data Mining | 1 | 2021 | 5 | 0.040 |
Why?
| | Rural Population | 1 | 2022 | 62 | 0.040 |
Why?
| | Health Status | 1 | 2021 | 31 | 0.040 |
Why?
| | Psychometrics | 1 | 2021 | 39 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 109 | 0.040 |
Why?
| | Ikaros Transcription Factor | 1 | 2020 | 3 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2020 | 17 | 0.040 |
Why?
| | Age Factors | 1 | 2021 | 250 | 0.040 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 14 | 0.040 |
Why?
| | Waiting Lists | 1 | 2019 | 12 | 0.040 |
Why?
| | Risk | 1 | 2019 | 42 | 0.040 |
Why?
| | Evidence-Based Practice | 1 | 2019 | 19 | 0.040 |
Why?
| | Policy | 1 | 2019 | 4 | 0.040 |
Why?
| | Algorithms | 1 | 2020 | 120 | 0.040 |
Why?
| | Perception | 1 | 2019 | 16 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 27 | 0.040 |
Why?
| | Cisplatin | 1 | 2019 | 10 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 419 | 0.040 |
Why?
| | Risk Factors | 1 | 2021 | 545 | 0.040 |
Why?
| | Patient Safety | 1 | 2019 | 25 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2019 | 63 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 61 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2019 | 74 | 0.040 |
Why?
| | Quality Improvement | 1 | 2019 | 95 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 117 | 0.040 |
Why?
| | Plasma | 1 | 2018 | 6 | 0.040 |
Why?
| | Kidney | 1 | 2019 | 107 | 0.040 |
Why?
| | Back | 1 | 2018 | 1 | 0.040 |
Why?
| | Abdomen | 1 | 2018 | 9 | 0.040 |
Why?
| | Thigh | 1 | 2018 | 6 | 0.030 |
Why?
| | Parents | 1 | 2019 | 218 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2015 | 31 | 0.030 |
Why?
| | Hospital Costs | 1 | 2015 | 34 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 67 | 0.030 |
Why?
| | Inpatients | 1 | 2015 | 44 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 30 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 255 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 61 | 0.030 |
Why?
| | Length of Stay | 1 | 2015 | 260 | 0.030 |
Why?
| | Models, Statistical | 1 | 2014 | 35 | 0.030 |
Why?
| | Transaminases | 1 | 2013 | 2 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 1 | 0.030 |
Why?
| | Plasmapheresis | 1 | 2013 | 3 | 0.030 |
Why?
| | Transplantation | 1 | 2013 | 2 | 0.030 |
Why?
| | Hemolysis | 1 | 2013 | 4 | 0.030 |
Why?
| | Everolimus | 1 | 2013 | 2 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 4 | 0.030 |
Why?
| | Cyclosporine | 1 | 2013 | 7 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2013 | 11 | 0.030 |
Why?
| | Medical Records | 1 | 2013 | 16 | 0.030 |
Why?
| | Penicillins | 1 | 2013 | 8 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 13 | 0.030 |
Why?
| | Nebraska | 1 | 2013 | 2 | 0.030 |
Why?
| | Intestinal Volvulus | 1 | 2013 | 9 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2013 | 13 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 9 | 0.030 |
Why?
| | Triglycerides | 1 | 2013 | 27 | 0.020 |
Why?
| | Nephrotic Syndrome | 1 | 2013 | 28 | 0.020 |
Why?
| | Hospitalization | 1 | 2015 | 286 | 0.020 |
Why?
| | Gastroschisis | 1 | 2013 | 18 | 0.020 |
Why?
| | Epithelium | 1 | 2012 | 4 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 15 | 0.020 |
Why?
| | Time Factors | 1 | 2013 | 280 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2012 | 246 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2010 | 30 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2010 | 86 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 5 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 5 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2007 | 6 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 17 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 27 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 126 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|